Claims for Patent: 7,289,840

Summary for Patent: 7,289,840

Title:	Method for monitoring early treatment response
Abstract:	Disclosed is a method for monitoring early treatment response of a cancer treatment comprising measuring by magnetic resonance spectroscopy (MRS), for example, proton MRS, the amount of Choline present in the cancerous tissue before and after treatment; the treatment comprises administration of a cell surface receptor inhibitor, for example, an EGFR inhibitor, whereby a decrease in the amount of Choline after treatment is indicative of a positive response. The decrease in the amount of Choline represents the decrease in the internal cell membrane as a result of down regulation of the organelles and their secretory granules and their transport vesicles. Disclosed also is a method for determining effectiveness of a cell surface receptor inhibitor in the treatment of cancer.
Inventor(s):	Norfray; Joseph F. (Glenview, IL)
Assignee:	Receptomon, LLC (Glenview, IL)
Application Number:	10/946,741
Patent Claims:	1. A method for monitoring early treatment response of a cancer treatment comprising measuring non-invasively, by Magnetic Resonance Spectroscopy (MRS), the amount of Choline present in the cancerous tissue before and after treatment, obtaining a difference between the Choline amounts, and correlating the difference with effectiveness of the cancer treatment or lack thereof; wherein the after treatment measurement is made within a period of about 168 hours of said treatment, wherein said treatment comprises administration of a cell surface receptor inhibitor. 2. The method of claim 1, wherein the MRS is based on the resonance of nuclei selected from the group consisting of .sup.31P, .sup.1H, .sup.13C, and .sup.23Na, and any combination thereof. 3. The method of claim 2, wherein the MRS is based on .sup.1H resonance. 4. The method of claim 1, wherein measuring the amount of Choline comprises measuring the height of a peak corresponding to Choline. 5. The method of claim 1, wherein measuring the amount of Choline comprises measuring the area under a peak corresponding to Choline. 6. The method of claim 1, wherein measuring the amount of Choline comprises measuring the ratio of the height of a peak corresponding to Choline relative to the height of peak of an internal standard. 7. The method of claim 6, wherein the internal standard is total creatine when the MRS is based on .sup.1H resonance. 8. The method of claim 6, wherein the internal standard is adenosine triphosphate (ATP) when the MRS is based on .sup.31P resonance. 9. The method of claim 1, wherein measuring the amount of Choline comprises measuring the ratio of the area under a peak corresponding to Choline relative to the area under a peak of an internal standard. 10. The method of claim 9, wherein the MRS is based on .sup.1H resonance and the internal standard is total creatine. 11. The method of claim 1, wherein the cell surface receptor is vascular endothelial growth factor receptor (VEGFR) or epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), platelet derived growth factor receptor (PDGFR), stem cell receptor (SCFR), nerve growth factor receptor (NGFR), hepatocyte growth factor (HGFR), insulin growth factor receptor (IGFR), a receptor having a tyrosine kinase domain, a receptor having a serine threonine kinase domain, a receptor utilizing a cytoplasmic tyrosine kinase, an angiogenesis factor receptor, or integrin receptor. 12. The method of claim 1, wherein measuring the amount of Choline comprises measuring the amount of choline, phosphocholine, phosphatidylcholine, lysophosphatidylcholine, or glycerophosphocholine, phosphomonoesters of choline, phosphodiesters of choline, phosphoethanolamine, glycerophosphoethanolamine, or any combination thereof. 13. The method of claim 1, wherein the amount of Choline is measured within a period of about 24 hours. 14. The method of claim 1, wherein the amount of Choline is measured within about 12 hours of said treatment. 15. The method of claim 1, wherein the cell surface receptor inhibitor is selected from the group consisting of gefitinib, erlotinib, cetuximab, canertinib, EKB-569, lapatinib, and any combination thereof. 16. The method of claim 1, wherein the cancer is selected from the group consisting of brain cancer, colorectal cancer, breast cancer, acute leukemia, lung cancer, kidney cancer, squamous cell cancer, testicular cancer, stomach cancer, melanoma, sarcomas, ovarian cancer, non-small cell lung cancer, esophageal cancer, pancreatic cancer, neuroblastoma, mesothelioma, prostate cancer, bone cancer, and heptocellular cancer. 17. The method of claim 1, wherein inhibition of the cell surface receptor causes an interruption in an up-regulated intracellular organelle. 18. The method of claim 17, wherein the interruption in the up-regulated intracellular organelle takes place in the secretory granules. 19. The method of claim 17, wherein the interruption in the up-regulated intracellular organelle takes place in the transporting vesicles. 20. The method of claim 1, wherein inhibition of the cell surface receptor causes an interruption in a function of the Golgi apparatus. 21. The method of claim 1, wherein inhibition of the cell surface receptor causes an interruption in a function of the lysosomes. 22. The method of claim 1, wherein inhibition of the cell surface receptor causes an interruption in a function of the endoplasmic reticulum. 23. The method of claim 1, wherein inhibition of the cell surface receptor causes an interruption in a function of the mitochondrion. 24. The method of claim 1, wherein inhibition of the cell surface receptor causes an interruption in a function of the nucleus. 25. The method of claim 1, wherein inhibition of the cell surface receptor causes an interruption in a function of the peroxisomes. 26. A method for monitoring cancer treatment comprising: (a) localizing a tumor in a patient; (b) selecting a region of interest (ROI) of the tumor; (c) obtaining magnetic resonance spectra (MRS) of the ROI; (d) measuring the amount of Choline from the MRS spectra; (e) initiating treatment comprising administering a cell surface receptor inhibitor; (f) obtaining MR spectra of the tumor at the same ROI within a period of 7 days of initiating treatment; (g) measuring the amount of Choline from the MR spectra; and (h) comparing the amount of Choline obtained before treatment with the amount of Choline obtained after treatment; and correlating a decrease in the amount of Choline after treatment with a positive response to treatment. 27. The method of claim 26, wherein the MR spectra of the tumor is obtained within 3 days of initiating treatment. 28. The method of claim 27, wherein the MR spectra of the tumor is obtained within 1 day of initiating treatment. 29. A method for determining effectiveness of a molecule as a drug for treating cancer comprising administering an amount of the molecule to an animal having a cancerous tissue and measuring non-invasively, by Magnetic Resonance Spectroscopy, the amount of Choline present in the cancerous tissue before and within a period of about 168 hours after administering the molecule, obtaining a difference between the Choline amounts, and correlating the difference with effectiveness of the cancer treatment or lack thereof; wherein said molecule comprises a cell surface receptor inhibitor. 30. A method for monitoring early treatment response of a cancer treatment comprising measuring non-invasively, by Magnetic Resonance Spectroscopy (MRS), the amount of Choline present in the intracellular membrane of the cancerous tissue before and after treatment, obtaining a difference between the Choline amounts, and correlating the difference with effectiveness of the cancer treatment or lack thereof; wherein the after treatment measurement is made within a period of about 168 hours of said treatment, wherein said treatment comprises administration of a cell surface receptor inhibitor.

Details for Patent 7,289,840

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2039-02-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2039-02-26